This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Axcelis (ACLS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Axcelis (ACLS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Axcelis (ACLS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Axcelis (ACLS) delivers healthy Q1 performance driven by momentum in the implant-intensive power device segment, especially silicon carbide and solid shipments to China.
Here's How Axcelis' (ACLS) is Placed Just Ahead of Q1 Earnings
by Zacks Equity Research
Axcelis' (ACLS) first-quarter performance is likely to have benefited from its leading position in the expanding power device market.
Axcelis Technologies (ACLS) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Axcelis Technologies (ACLS) closed at $97.24 in the latest trading session, marking a +1.95% move from the prior day.
Axcelis Technologies (ACLS) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Axcelis Technologies (ACLS) closed the most recent trading day at $95.38, moving +0.62% from the previous trading session.
Axcelis Technologies (ACLS) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
Axcelis Technologies (ACLS) reachead $104.33 at the closing of the latest trading day, reflecting a -0.27% change compared to its last close.
New Strong Sell Stocks for April 11th
by Zacks Equity Research
AMN, ACLS and GME have been added to the Zacks Rank #5 (Strong Sell) List on April 11, 2024.
Axcelis Technologies (ACLS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Axcelis Technologies (ACLS) stood at $105.24, denoting a +0.75% change from the preceding trading day.
Axcelis (ACLS) Announces Purion Implanter Shipments to Japan
by Zacks Equity Research
Axcelis' (ACLS) top line is propelled by robust customer demand for Purion suite of products.
Axcelis Technologies (ACLS) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Axcelis Technologies (ACLS) closed at $112.39 in the latest trading session, marking a +0.78% move from the prior day.
Axcelis Technologies, Inc. (ACLS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Axcelis (ACLS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Brokers Suggest Investing in Axcelis (ACLS): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Axcelis (ACLS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Why Axcelis Technologies (ACLS) Dipped More Than Broader Market Today
by Zacks Equity Research
Axcelis Technologies (ACLS) concluded the recent trading session at $108.04, signifying a -1.38% move from its prior day's close.
Axcelis' (ACLS) Purion Solution Continues to Witness Traction
by Zacks Equity Research
Axcelis (ACLS) top-line performance is driven by strong adoption of Purion family of products.
Axcelis (ACLS) Ships Purion Implanters to Chinese Chipmakers
by Zacks Equity Research
Axcelis' (ACLS) Purion M SiC implanters are set to assist power device chipmakers in China to tackle technical challenges.
Axcelis Technologies (ACLS) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Axcelis Technologies (ACLS) reachead $111.16 at the closing of the latest trading day, reflecting a +0.86% change compared to its last close.
Investors Heavily Search Axcelis Technologies, Inc. (ACLS): Here is What You Need to Know
by Zacks Equity Research
Axcelis (ACLS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Axcelis Technologies (ACLS) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
The latest trading day saw Axcelis Technologies (ACLS) settling at $112.48, representing a +0.51% change from its previous close.
Wall Street Bulls Look Optimistic About Axcelis (ACLS): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Axcelis (ACLS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Axcelis Technologies, Inc. (ACLS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Axcelis (ACLS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Axcelis Technologies, Inc. (ACLS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Axcelis (ACLS). This makes it worthwhile to examine what the stock has in store.
Wall Street Analysts Think Axcelis (ACLS) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Axcelis (ACLS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
New Strong Sell Stocks for February 14th
by Zacks Equity Research
AROW, ACLS and BP have been added to the Zacks Rank #5 (Strong Sell) List on February 14, 2023.
Investors Heavily Search Axcelis Technologies, Inc. (ACLS): Here is What You Need to Know
by Zacks Equity Research
Axcelis (ACLS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
New Strong Sell Stocks for February 12th
by Zacks Equity Research
ACLS, BMY and CHX have been added to the Zacks Rank #5 (Strong Sell) List on February 12, 2023.